Design of stents for enhanced endurance and flexibility. Investigation of design possibilities involving auxetic tubular structures

SCHEME: CORE

CALL: 2009

DOMAIN: MS - New Functional and Intelligent Materials and Surfaces

FIRST NAME: Ahmed

LAST NAME: Makradi

INDUSTRY PARTNERSHIP / PPP: No

INDUSTRY / PPP PARTNER:

HOST INSTITUTION: LIST

KEYWORDS: Intelligent materials, stents, high-cycle fatigue, stent flexibility, auxetic structures, finite element analysis, simulation-based design

START: 2010-02-01

END: 2013-05-31

WEBSITE: https://www.list.lu/

Submitted Abstract

The aim of this project is to develop new designs for biomedical stents with special focus on optimizing deliverability and reducing long-term complications occasioned by unexpected in vivo failure of the stent due to high-cycle fatigue. Two types of metallic platforms commonly used for manufacturing stents will be considered: AISI 316L stainless steel and medical-grade Nitinol . Developing auxetic designs, which appears to be a very recent trend in stent design, will also be investigated. Recent reports indicate that designs with auxetic properties might be able to enhance flexibility while maintaining sufficient radial strength for the deployed stent (Dolla et al., 2007).Stents are tubular devices that are introduced in narrowed vessels to prevent re-occlusion of a diseased region following angioplasty. The treatment of flow restriction in body lumens by means of percutaneous angioplasty and stenting is a minimally invasive technique that can advantageously replace surgical bypass in specific situations (see e.g. Lagerqvist et al. 2007, Serruys et al., 1994). Early stent designs were introduced in 1969 by Dr. Charles Dotter (C.T. Dotter, 1969) and consisted of simple stainless steel coil springs. Nowadays, stenting is a well established technique in interventional radiology and research is ongoing to optimize existing stent designs in order to facilitate delivery into smaller or more complicated lumen configurations and to overcome persisting clinical complications, like device-induced thrombosis due to cell proliferation within the stent, unexpected in vivo failure, etc.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement